Research
Hormonal
Women with PCOS have an increased proportion of atherogenic small dense LDL particles and elevated Lipoprotein(a), which are independent risk factors for cardiovascular disease.
Request a complete lipid panel that includes Lipoprotein(a) and ApoB/ApoA-I, not just standard LDL-C. Even if your LDL is normal, elevated Lp(a) and small dense LDL particles common in PCOS increase heart disease risk. Statins may be necessary to address these specific abnormalities.
GoodSupportsHIGH confidence
Women with PCOS have an increased proportion of atherogenic small dense LDL or decreased mean LDL particle size... Lipoprotein (a) concentration in women with PCOS has been reported in some studies... non-obese women with PCOS presented a significantly higher level of lipoprotein (a) than matched controls
Why this rating
Consistent findings across multiple studies, though one Korean study showed no qualitative LDL change in non-obese women.
Source
Dyslipidemia in women with polycystic ovary syndrome
Jinju Kim et al. · Obstetrics & Gynecology Science · 2013
DOI 10.5468/ogs.2013.56.3.137
narrative_reviewCited 185×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle modification (diet and exercise) is the first-line therapy for dyslipidemia in PCOS, and statins are a novel therapeutic approach that improves lipid profiles and reduces testosterone and insulin resistance.Strong
- Women with polycystic ovary syndrome (PCOS) exhibit a distinct dyslipidemic profile characterized by elevated triglycerides, elevated LDL cholesterol, and reduced HDL cholesterol compared to controls, independent of obesity status.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →